June 3, 2021: Kaposi sarcoma despite ART; heat-based cervical HPV treatment; re-evaluating HIV-associated neurocognitive disorder; HIV and diabetes in Texas.
April 22, 2021: Weight gain and CVD risk after treatment initiation; stroke type divergence among PLWH; exercise and CD4; a new approach to pain research in HIV.
David Alain Wohl, M.D., on new findings from CROI 2021 that help us better understand the connections between sleep, diet, and quality of life among people living with HIV.
Hypertension Control Emerges as Key Concern in Examination of HIV, Aging, and Cardiovascular Disease
David Alain Wohl, M.D., talks through new data presented at CROI 2021 that further our understanding of the interplay between HIV and comorbidities we often associate with aging, particularly those related to cardiovascular disease.
March 25, 2021: HIV disease progression spikes in a London hospital; neurocognitive impairment and frailty in PLWH; the smell of HIV-associated neurocognitive disorder; statin usage and physical function decline.
Two studies out of Europe aimed to give data on which patients with HIV benefit most from lipid-lowering medications, but they both ultimately concluded that better CVD risk-assessment tools—targeted specifically for PLWH—are needed.
Feb. 11, 2021: Early comorbidity development among women living with HIV; type 2 heart attack frequency; assessing European-based CVD assessment tools; long-term cognitive dysfunction and HIV/hepatitis coinfection.
Nov. 19, 2020: Metformin's effect on weight and gut microbiota; integrase and cardiometabolics in women with HIV; ongoing link between HIV, smoking, and cancer; how early HIV treatment initiation impacts future cervical cancer outcomes.
Oct. 8, 2020: HPV-related cancer risk among women living with HIV; the interplay between HIV, HBV, and liver disease; Framingham vs. other tools to gauge statin value; integrase inhibitors, weight gain, and menopause.
Sept. 24, 2020: HIV adherence cohorts usually fail to reflect the diversity of the epidemic; HIV thrives in deprived neighborhoods; rethinking barriers to rapid HIV treatment initiation; long-term adverse events on INSTIs vs. efavirenz.